Only a small share of AI ideas in clinical development ever make it into validated, repeatable operations. That gap matters more than market excitement, because executive teams do not fund experiments indefinitely. They fund cycle-time reduction, lower screening costs, better enrollment performance, and clearer portfolio decisions. For clinical leaders, the question is not whether AI […]